Biomarkers of NRF2 signalling: Current status and future challenges

Autor: Christina Morgenstern, Isabel Lastres-Becker, Birsen Can Demirdöğen, Vera Marisa Costa, Andreas Daiber, Roberta Foresti, Roberto Motterlini, Sibel Kalyoncu, Burak I. Arioz, Sermin Genc, Monika Jakubowska, Ioannis P. Trougakos, Aleksandra Piechota-Polanczyk, Michel Mickael, Marlene Santos, Thomas W. Kensler, Antonio Cuadrado, Ian M. Copple

Publikováno v: Redox Biology, Vol 72, Iss , Pp 103134- (2024)

The cytoprotective transcription factor NRF2 regulates the expression of several hundred genes in mammalian cells and is a promising therapeutic target in a number of diseases associated with oxidative stress and inflammation. Hence, an ability to mo

Externí odkaz: https://doaj.org/article/f50d81e6b4e544bc8942767d3919a61a

Specific targeting of the NRF2/β-TrCP axis promotes beneficial effects in NASH

Autor: Raquel Fernández-Ginés, José Antonio Encinar, Maribel Escoll, Daniel Carnicero-Senabre, José Jiménez-Villegas, Ángel J. García-Yagüe, Águeda González-Rodríguez, Irma Garcia-Martinez, Ángela M Valverde, Ana I. Rojo, Antonio Cuadrado

Publikováno v: Redox Biology, Vol 69, Iss , Pp 103027- (2024)

Non-alcoholic steatohepatitis (NASH) is a common chronic liver disease that compromises liver function, for which there is not a specifically approved medicine. Recent research has identified transcription factor NRF2 as a potential therapeutic targe

Externí odkaz: https://doaj.org/article/55f0658f6cd7407d98a9c86477d2e394

Drug repurposing on Alzheimer's disease through modulation of NRF2 neighborhood

Autor: Marilena M. Bourdakou, Raquel Fernández-Ginés, Antonio Cuadrado, George M. Spyrou

Publikováno v: Redox Biology, Vol 67, Iss , Pp 102881- (2023)

Alzheimer's disease (AD) is an age-dependent neurodegenerative disorder and the most common cause of cognitive decline. The alarming epidemiological features of Alzheimer's disease, combined with the high failure rate of candidate drugs tested in the

Externí odkaz: https://doaj.org/article/ad3ea2aca98b470d8aa8c808fb6a5417

Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)

Autor: Fiorinni, Giulia, Saracino, Ilaria Maria, Carrasco, Manuel Pabon, Huerga, Alma Keco, Almajano, Enrique Alfaro, Martinez Dominguez, Samuel Jesus, Galan, Horacio Alonso, Velayos, Benito, Sadornil, Carmen Dueñas, Botargues Bote, Jose Maria, Gonzalez-Cordero, Pedro Luis, Areia, Miguel, Gomez Rodriguez, Blas Jose, Pellicano, Rinaldo, Nuñez, Óscar, Franceschi, Francesco, Alekseenko, Sergey, Perona, Monica, Abdulkhakov, Rustam, Dominguez-Cajal, Manuel, Notari, Pedro Almela, Camarero, Judith Gomez, Moreno, Manuel Jimenez, Algaba, Alicia, Bermejo, Fernando, Tejada, Javier Tejedor, Susanibar, Elida Oblitas, Boltin, Doron, Georgopoulos, Sotirios, OMorain, Colm, Qasim, Asghar, Beales, Ian, Bakulina, Natalia, Fadeenko, Galina, Malfertheiner, Peter, Rosania, Rosa, Ilchishina, Tatiana, Bogomolov, Pavel, Bakulin, Igor, Zaytsev, Oleg, Gravina, Antonietta Gerarda, Romano, Marco, Di Leo, Alfredo, Losurdo, Giuseppe, Grigorieva, Ludmila, Guillena, Pedro Delgado, Marusic, Marinko, Jurcic, Dragan, Dekhnich, Natalia Nikolaevna, Iyo, Eduardo, de la Peña Negro, Luisa Carmen, Baryshnikova, Natalia, Bakanova, Natalia, Simsek, Halis, Simsek, Cem, Gridnyev, Oleksiy, Fernandez-Bermejo, Miguel, Angueira, Teresa, Ruiz-Zorrilla Lopez, Rafael, Gomez, Barbara, Kovacheva-Slavova, Mila, Lahat, Adi, Alcedo, Javier, Campillo, Ana, Belousova, Liya Nikolaevna, Villarroya, Ramon Pajares, Ljubicic, Neven, Nikolic, Marko, González-Santiago, Jesús M., Santamaría, Diego Burgos, Pakhomova, Anna, Sekulic-Spasic, Izabela, Ghisa, Matteo, Farinati, Fabio, Sagdati, Sabir Irfan, Panic, Nikola, Heluwaert, Frederic, Amorena, Edurne, Moreira, Leticia, Esparrach, Gloria Fernandez, Plotnikova, Ekaterina Yuryevna, Kukla, Michal, Kamburov, Victor, Lamuela Calvo, Luis Javier, Rankovic, Ivan, Lavín, Antonio Cuadrado, Lazaro, Yolanda Arguedas, Carrera Agnieszka Dobrowolska, Victor Gonzalez, Eder, Piotr, Kononova, Alla, Nyssen, Olga P., Vaira, Dino, Pérez Aísa, Ángeles, Rodrigo, Luis, Castro-Fernandez, Manuel, Jonaitis, Laimas, Tepes, Bojan, Vologzhanina, Liudmila, Caldas, María, Lanas, Angel, Lucendo, Alfredo J., Bujanda, Luis, Ortuño, Juan, Barrio, Jesús, Huguet, Jose M., Voynovan, Irina, Lasala, Jorge Perez, Sarsenbaeva, Aiman Silkanovna, Fernandez-Salazar, Luis, Molina-Infante, Javier, Jurecic, Natasa Brglez, Gasbarrini, Antonio, Kupčinskas, Juozas, Bordin, Dmitry, Marcos-Pinto, Ricardo, Lerang, Frode, Leja, Marcis, Buzas, Gyorgy M., Niv, Yaron, Rokkas, Theodore, Phull, Perminder, Smith, Sinead, Shvets, Oleg, Venerito, Marino, Milivojevic, Vladimir, Simsek, Ilkay, Lamy, Vincent, Bytzer, Peter, Boyanova, Lyudmila, Kunovský, Lumír, Beglinger, Christoph, Doulberis, Michael, Marlicz, Wojciech, Goldis, Adrian, Tonkić, Ante, Capelle, Lisette, Puig, Ignasi, Megraud, Francis, Morain, Colm O’, Gisbert, Javier P.

Publikováno v: In Clinical Gastroenterology and Hepatology October 2022 20(10):2243-2257

Personalized redox medicine in inflammatory bowel diseases: an emerging role for HIF-1α and NRF2 as therapeutic targets

Autor: Arno R. Bourgonje, Damian Kloska, Anna Grochot-Przęczek, Martin Feelisch, Antonio Cuadrado, Harry van Goor

Publikováno v: Redox Biology, Vol 60, Iss , Pp 102603- (2023)

Inflammatory bowel diseases (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), are intimately associated with inflammation and overproduction of reactive oxygen species (ROS). Temporal and inter-individual variabilities in disease

Externí odkaz: https://doaj.org/article/0fbaa4e93d704d2bac68dbd106eeab49